Vaccine Immunotherapy for Pediatric Brain Cancer
(Re-MATCH Trial)

Recruiting in Palo Alto (17 mi)

+2 other locations

Overseen ByDuane Mitchell, MD, PhD

Age: < 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: University of Florida

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?This trial uses special immune cells and vaccines made from the patient's tumor to treat children with recurring brain tumors. The goal is to help their immune system recognize and destroy cancer cells, offering a new option for those who do not respond well to traditional treatments.

Eligibility Criteria

This trial is for children and young adults up to 30 years old with a first recurrence of medulloblastoma or primitive neuroectodermal tumors after radiotherapy. Participants need stable neurological function, adequate blood counts, normal kidney and liver function, and must agree to use birth control. Those with genetic risks for radiation-induced cancers are also eligible.

Inclusion Criteria

I am 30 years old or younger.

Signed informed consent according to institutional guidelines must be obtained prior to registration

My neurological symptoms have been stable for at least a week.

+7 more

Exclusion Criteria

I do not have HIV, Hepatitis B or C, or any known immunosuppressive disease.

Patients receiving any other concurrent anticancer or investigational drug therapy

I am taking medication that weakens my immune system for another health issue.

+6 more

Participant Groups

The study tests tumor-specific immune cells (TTRNA-xALT) and dendritic cell vaccines (TTRNA-DCs) on about 35 patients with recurrent brain tumors. It aims to see how these immunotherapies affect the tumor's progression based on prior success in adult cancer treatments.

2Treatment groups

Experimental Treatment

Group I: Group BExperimental Treatment2 Interventions

NMA Salvage chemotherapy plus peripheral blood stem cell transplant followed by TTRNA-xALT and TTRNA-DCs.

Group II: Group AExperimental Treatment2 Interventions

High dose chemotherapy plus peripheral blood stem cell transplant followed by TTRNA-xALT and TTRNA-DCs.